CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Angiotensin IIWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1229 Interleukin-1 receptor antagonist Wiki 1.00
drug570 Cholecalciferol Wiki 1.00
drug1270 Ivermectin Wiki 0.24
drug262 Azithromycin Wiki 0.17

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome

This study aims to find out whether the use of angiotensin II, which is a drug to raise blood pressure has been approved by European Medical Agency in August 2019, as an add-on medication to increase blood pressure in patients with COVID-19, acute severe lung injury, inflammation and severe shock, compared with standard medication. In addition, the investigators will collect the data of Anakinra, another drug which is frequently used in this condition to reduce inflammation. The investigators will collect clinical data and outcomes from critical care patients. The investigators will analyse for whom these drugs are most beneficial and explore whether there are any patients who don't benefit or have side effects.

NCT04408326 COVID Acute Respiratory Distress Syndrome Drug: Angiotensin II Drug: Interleukin-1 receptor antagonist
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: Percentage

Measure: Proportions of patients with mean arterial pressure ≥ 65 mmHg or an increase of mean arterial pressure ≥10 mmHg at 3 hours

Time: 3 hours

Secondary Outcomes

Description: microgram/kg/min

Measure: Noradrenaline dose

Time: 1 hour and 3 hours

Description: Changes in score, minimum 0, maximum 24, the higher score showing worse prognosis

Measure: Sequential Organ Failure Assessment (SOFA) score

Time: baseline, 24, and 48 hours

Description: Patients who are alive and do not require renal replacement therapy at 28 days

Measure: RRT-free days

Time: 28 days

Description: Proportions of patients who do not require renal replacement therapy

Measure: RRT discontinuation

Time: 7 and 28 days

Description: micromol/L

Measure: Serum creatinine

Time: 7 days and 28 days

Description: Changes in value

Measure: PaO2/FiO2 ratio

Time: baseline, 24, and 48 hours

Description: Mortality rate

Measure: Mortality

Time: 7 days and 28 days

Description: e.g. arrhythmia, thromboembolism, etc.

Measure: Adverse events

Time: 28 days

Description: Change in serum C-reactive protein

Measure: Change in serum C-reactive protein

Time: 7 days

Description: Change in serum ferritin

Measure: Change in serum ferritin

Time: 7 days


No related HPO nodes (Using clinical trials)